tiprankstipranks
Sarepta expects to exceed FY22 guidance for net product revenues
The Fly

Sarepta expects to exceed FY22 guidance for net product revenues

Sarepta Therapeutics reported preliminary fourth quarter and full-year 2022 net product revenues as part of their presentation today at the 41st Annual J.P. Morgan Healthcare Conference. Q4 net product revenues are expected to be approximately $235.5M, a 32% increase over the same period in 2021. Expected net product revenues do not include collaboration revenues, the company noted. FY22 net product revenues are expected to be $843.3M, a 38% increase over the same period of 2021, which is also expected to exceed Sarepta’s net product revenue guidance of $825M-$840M. Again, expected net product revenues do not include collaboration revenues. As of December 31, 2022, the company had preliminary cash, cash equivalents, restricted cash and investments of approximately $2.0B, as compared to approximately $2.1B as of December 31, 2021. "We are pleased to have closed out 2022 on an extremely strong note with continued execution across our three RNA-based PMO therapies, delivering net product revenue that is expected to exceed our upwardly revised guidance range. These preliminary results reflect the mission-driven dedication and expertise of our teams to serve the nearly 30% of Duchenne patients who are amenable to one of our approved therapies," said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. "These preliminary selected financial results are unaudited and subject to adjustment. Sarepta will report its final and complete fourth quarter and full-year 2022 financial results in late February 2023. The Company has not completed its financial closing procedures for the quarter or year ended December 31, 2022 and its actual results could be materially different from these preliminary financial results," the company noted.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on SRPT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles